Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
The Genetics Podcast - Precision Pioneers EP 5: Alnylam's Josh Friedman on developing precision medicines for the 'silent killer' NASH/NAFLD

Precision Pioneers EP 5: Alnylam's Josh Friedman on developing precision medicines for the 'silent killer' NASH/NAFLD

The Genetics Podcast

05/05/21 • 2068 min

plus icon
bookmark
Share icon
On this episode of the podcast, Patrick is joined by Josh Friedman, Senior Director of Research at Alnylam Pharmaceuticals. Alnylam works on the discovery and development of RNA interference therapeutics; treatments for genetic diseases which work by ‘switching off’ the specific genes associated with a given condition. In this fifth episode of our precision pioneers miniseries, we explore how RNA interference can be applied to treat common and rare genetic diseases, and dive deep into the genetics of non-alcoholic fatty liver disease and NASH.

05/05/21 • 2068 min

plus icon
bookmark
Share icon

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/the-genetics-podcast-279637/precision-pioneers-ep-5-alnylams-josh-friedman-on-developing-precision-34489580"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to precision pioneers ep 5: alnylam's josh friedman on developing precision medicines for the 'silent killer' nash/nafld on goodpods" style="width: 225px" /> </a>

Copy